BCA
VRCA icon

Berman Capital Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Berman Capital Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14
Closed -$1K – 1785
2020
Q2 		$1K Buy
+14
New +$1.62K ﹤0.01% 1517

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berman Capital Advisors's VRCA Position: Q3 2020 in Review

Berman Capital Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q3 2020, closing a stake of 14 shares — an estimated $1K sold.

Berman Capital Advisors first reported a position in VRCA in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 47 funds tracked by Wall St. Rank hold VRCA as of Q3 2020.

  • Berman Capital Advisors reported no remaining Verrica Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Berman Capital Advisors sold 14 Verrica Pharmaceuticals shares in Q3 2020, an estimated $1K.
  • Berman Capital Advisors first reported a position in Verrica Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Berman Capital Advisors's Verrica Pharmaceuticals position peaked at $1K in Q2 2020.
  • 47 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2020.

Based on Berman Capital Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.